Evaluation of safety and efficacy in prostate cancer patients treated with focal low-dose-rate brachytherapy

Evaluation of safety and efficacy in prostate cancer patients treated with focal low-dose-rate brachytherapy - Focal prostate brachytherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030509

Enrollment

Registered

2018-02-01

Start date

2018-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Focal low-dose-rate brachytherapy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Biopsy proven prostate cancer. 2) Biopsy positive core rate <=50%. 3) Tumor size not extended half of prostate volume on MRI. 4) Targeted biopsy proven prostate cancer that was detected on MRI. 5) No regional lymph node metastasis. 6) No distant metastasis. 7) Approved by document.

Exclusion criteria

Exclusion criteria: 1) >= Clinical T3a 2) Gleason score >=9 3) Other prostate therapy has been performed including TURP, HoLEP, hyperthermia, and castration 4) History of prostate radiotherapy 5) Lead principal investigator judged inappropriate to enroll the present study.

Design outcomes

Primary

Measure	Time frame
Probability of acute adverse events	—

Secondary

Measure	Time frame
Biochemical relapse free survival,overall survival, cancer-specific survival, clinical relapse free survival	—

Countries

Japan

Contacts

Public ContactHideyasu Tsumura

Kitasato University School of Medicine Urology

tsumura@med.kitasato-u.ac.jp0427789091

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026